News

Enzymes Linked to Huntington’s Seen for 1st Time in Living Brain

Scientists at the Martinos Center for Biomedical Imaging at Massachusetts General Hospital were able — for the first time — to track epigenetic factors, or non-genetic influences on gene activity, linked to Huntington’s disease in the brains of living humans. The study, “Insights into neuroepigenetics through human histone…

Promising Huntington’s Therapy Candidate Discussed at Hereditary Disease Foundation Meeting

About 300 international scientists and industry leaders recently gathered in Cambridge, Massachusetts, for the Hereditary Disease Foundation‘s 10th biennial “Milton Wexler Celebration of Life” Symposium, to promote collaborations that can take scientific findings from the laboratory into the lives of patients as treatments. One of the highlights of the meeting,…

Protein Identified That Protects Cells from Neurodegenerative Diseases, Possibly Leading to New Therapies

The accumulation of toxic protein aggregates within nerve cells are a hallmark of neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s, or Huntington’s disease. Now, researchers at the University of Glasgow in Scotland have identified a protein called UBQLN2 that protects against such diseases by eliminating those protein aggregates. The study, “…

Vaccinex’s VX15 Antibody for Huntington’s Fast Tracked by FDA

Vaccinex‘s VX15, a novel clinical stage monoclonal antibody for Huntington’s disease (HD) treatment, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). VX15 blocks the activity of semaphorin 4D (SEMA4D), a molecule that is thought to promote chronic inflammatory responses in the brain. “We are very pleased…

Huntington’s Drug Candidate Huntexil Can Trigger Neuroprotection

Huntexil (pridopidine), a drug candidate intended to treat Huntington’s disease movement symptoms, might have a more intricate way of acting on the brain than researchers previously believed — by ramping up activity in molecular pathways known to promote neuroprotection. In the study “Pridopidine activates neuroprotective pathways impaired in…

Monkey Models Show Human Symptoms of Huntington’s Disease

Scientists at Yerkes National Primate Research Center, Emory University have shown that transgenic monkeys for Huntington’s disease exhibit early emergent symptoms, like humans with the disease, which bolsters the idea that monkeys could be effective animal models for developing therapies. The study, “Increased irritability, anxiety, and immune reactivity in transgenic Huntington’s disease monkeys,”…